Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
NCT00161031
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
Atomoxetine
Sponsor
University of Maryland, Baltimore